Loading...

ARWR ARROWHEAD PHARMACEUTICALS INC Capital Structure Changes 8-K Filing

RRWH

RWR

ARROWHEAD PHARMACEUTICALS INC

(ARWR)

2026 8-K

Financial Results Update

Annual Meeting Results

Financial Results

Debt Issuance Details

Equity Offering Announcement

Clinical Trial Results

Financial Results Announcement

FDA Approval Announcement

Patent Dispute Update

Litigation Update

License Agreement

Financial Statements

Financial Statements

Annual Meeting Results

Financial Results

Director Appointment

Financial Results

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Amendment to Board Appointment

Appointment of Director

Financial Results Announcement

Departure of Directors

Agreement for Stock Offering

Dismissal of independent re...

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

External Links:

On January 12, 2026, Arrowhead Pharmaceuticals, Inc. issued $700 million in 0.00% Convertible Senior Notes due 2032, with an option for underwriters to purchase an additional $75 million.

AI Assistant

ARROWHEAD PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.